Dual-phase 18F-FDG PET can predict lung adenocarcinoma outcome

03/31/2010 | HealthImaging.com

A study involving patients with histologically confirmed lung adenocarcinoma found that the change in maximal standardized uptake values between early and delayed 18F-FDG PET can be a strong singular predictor of patient outcome and aid in patient management. "Patients with more than 25 percent increase in SUVmax had a median survival of 15 months, compared with 39 months for those with less than 25 percent increase in SUVmax," the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC